Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: siRNA therapeutics - Sirnaomics

Drug Profile

Research programme: siRNA therapeutics - Sirnaomics

Alternative Names: Acurita; STP523; STP601; STP801; STP805; STP900; STP909; STP911; STP916

Latest Information Update: 05 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sirnaomics
  • Developer Guangdong Zhongsheng Pharmaceutical; Sirnaomics
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections
  • No development reported Age-related macular degeneration; Eye disorders; Glioblastoma; Human papillomavirus infections; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Respiratory syncytial virus infections; Spinal cord injuries; Transplant rejection

Most Recent Events

  • 27 Jan 2020 Early research in COVID-2019-infections (Prevention) in China (unspecified route)
  • 27 Jan 2020 Early research in COVID-2019-infections (Prevention) in USA (unspecified route)
  • 27 Jan 2020 Early research in COVID-2019-infections in China (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top